FDA Working On QT Interval Guidance Under Cardio-Renal’s Throckmorton

FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is the chair of an agency working group that is attempting to provide clear advice to industry on how to assess drugs that prolong the QT interval